Low Serum Interleukin-13 Levels Correlate with Poorer Prognoses for Colorectal Cancer Patients
Authors:
- 1 January 2014
- journal article
- Published by International College of Surgeons in International Surgery
- Vol. 99 (3) , 223-229
Abstract
Interleukin-13 (IL-13) is an immunosuppressive cytokine produced by several immune cells and cancer cells. The aim of this retrospective study was to determine if serum IL-13 levels have an association with clinical outcome in patients with colorectal cancer. A total of 241 patients with colorectal cancer were enrolled in the present study. Preoperative serum IL-13 concentrations were measured by enzyme-linked immunosorbent assay. We analyzed the association of serum IL-13 levels with clinicopathological variables. Patients with lymph node metastasis, lymphatic invasion, vascular invasion, distant metastases or advanced stage of disease had significantly lower serum IL-13 levels. Low serum IL-13 was significantly associated with both poor recurrence-free and overall survival. Multivariate analysis showed that low IL-13 levels were an independent predictive marker for poor prognosis. In conclusion, our data suggest that low serum IL-13 levels may be a useful predictive marker for poor prognosis in colorectal cancer.Keywords
This publication has 28 references indexed in Scilit:
- Genetic dissection of eosinophilic esophagitis provides insight into disease pathogenesis and treatment strategiesJournal of Allergy and Clinical Immunology, 2011
- A striking local esophageal cytokine expression profile in eosinophilic esophagitisJournal of Allergy and Clinical Immunology, 2011
- The role of IL-13 and NK T cells in experimental and human ulcerative colitisMucosal Immunology, 2008
- Distinct roles for IL-13 and IL-4 via IL-13 receptor α1 and the type II IL-4 receptor in asthma pathogenesisProceedings of the National Academy of Sciences, 2008
- Immunosuppressive networks in the tumour environment and their therapeutic relevanceNature Reviews Cancer, 2005
- Tumor cells secreting IL-13 but not IL-13R 2 fusion protein have reduced tumorigenicity in vivoInternational Immunology, 2004
- Circulating Levels of Interleukin-10 and Interleukin-6 in Gastric and Colon Cancer Patients Before and After Surgery: Relationship with Radicality and OutcomeJournal of Interferon & Cytokine Research, 2002
- An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2–dominated inflammatory responseJournal of Clinical Investigation, 1999
- Interleukin-13 Receptors on Human Prostate Carcinoma Cell Lines Represent a Novel Target for a Chimeric Protein Composed of IL-13 and a Mutated Form of Pseudomonas ExotoxinJournal of Urology, 1997
- Experimental gene therapy of cancer using tumor cells engineered to secrete interleukin‐13European Journal of Immunology, 1995